Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Cash from Operations: 2019-2024

Historic Cash from Operations for GeneDx Holdings (WGS) over the last 6 years, with Dec 2024 value amounting to -$28.5 million.

  • GeneDx Holdings' Cash from Operations rose 458.75% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.2 million, marking a year-over-year increase of 160.15%. This contributed to the annual value of -$28.5 million for FY2024, which is 84.18% up from last year.
  • As of FY2024, GeneDx Holdings' Cash from Operations stood at -$28.5 million, which was up 84.18% from -$180.1 million recorded in FY2023.
  • GeneDx Holdings' 5-year Cash from Operations high stood at -$28.5 million for FY2024, and its period low was -$319.2 million during FY2022.
  • In the last 3 years, GeneDx Holdings' Cash from Operations had a median value of -$180.1 million in 2023 and averaged -$175.9 million.
  • In the last 5 years, GeneDx Holdings' Cash from Operations plummeted by 397.27% in 2020 and then skyrocketed by 84.18% in 2024.
  • GeneDx Holdings' Cash from Operations (Yearly) stood at -$93.1 million in 2020, then crashed by 104.49% to -$190.4 million in 2021, then plummeted by 67.59% to -$319.2 million in 2022, then skyrocketed by 43.56% to -$180.1 million in 2023, then surged by 84.18% to -$28.5 million in 2024.